Home
Account
Research Tools & Data
Educate
Contribute
News
ETFs
Sectors
About
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Economic Calendar
Chart School
Tutorials
Learning Center
Submit Article
Join Blog Network
Chat Rooms
Rate Broker
Rate Software
About Us
Contact Us
Advertise With Us
Terms and Conditions
Emergent BioSolutions Hits Investors Business Daily
By:
TraderMark
Monday, December 01, 2008 2:58 PM
Symbols:
AVAV
,
EBS
,
VXGN
Email Article
Bookmark:
Font Size
Print Article
In 2004, the government set aside $5.6 billion under its Project BioShield to develop and stockpile next-generation vaccines to protect Americans from bioterrorism.
In May, Emergent bought a recombinant vaccine formula from former rival VaxGen (OTC BB:
VXGN.OB
-
News
) for a mere $2 million. VaxGen had spent millions developing its vaccine, but it lost a government contract worth $877.5 million for 75 million doses because of problems with the drug's stability. Since buying the vaccine, Emergent has invested millions more to improve its stability.
Emergent has other products in the pipeline as well. It is working on two drugs to treat the anthrax toxins for people already infected. It has two botulinum vaccines in development and other vaccines or treatments for typhoid, tuberculosis, chlamydia and hepatitis B.
Earlier this year, Emergent tried to buy Protein Sciences and its promising flu vaccine that is in the late stages of testing and approval. But after both sides announced the deal worth up to $78 million in May, Protein Sciences appears to have balked. It said in July that the deal was off. Emergent says it's still on, and analysts say the deal is now in the hands of lawyers.
The company posted third-quarter earnings per share of 34 cents, up 240% from a year ago. Analysts polled by Thomson Reuters had expected just 18 cents. Sales were $56.6 million, up 30%.
Emergent's future isn't certain. There's no guarantee that the company will win the race for the more-advanced anthrax vaccine. But analysts think it will probably get at least part of some future contracts. Also, being so closely tied to any one customer is dangerous. But in the current market, there are worse customers than Uncle Sam. "
It's nice to have a customer like the U.S. government, which at this point still a pretty creditworthy entity
," Moskowitz said. (
oh, is it?
)
Long Emergent BioSolutions in fund and personal account
Next Page >>
<< Previous Page
1
2
Bookmark:
Email Article
Print Article
Related Stories
Research Related Stocks:
AVAV
,
EBS
,
VXGN
,
More Articles on:
Medical
,
Aerospace
Top CEOs to Launch Electrification Coalition
Biostar Raises $3.6 Million
Bulls Back On Track?
Ford's Main Problem: The UAW's Crippling Job Classifications And Work Rules
Emergent BioSolutions Reports Financial Results for Third Quarter and First Nine Months of 2009
Rate this Commentary
Comments
(0)
No Comments
Post Comment
Name:
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
Advertisement
Related Press Releases
OXiGENE to Acquire VaxGen in a Stock-for-Stock Merger
AeroVironment Announces Establishment of 10b5-1 Trading Plan By Chief Executive Officer
The VaxGen Full Value Committee Nominates Five Highly Qualified Candidates to Replace Current VaxGen Board
AeroVironment,Inc. Announces Fiscal 2010 First Quarter Results
Biotech Cools Off in August But Capital Markets Remain Positive
Popular Articles
Apple Inc (AAPL): Weaker Dollar Will Benefit Revenue Growth And Margins
By:
Financial Alchemist
GE's $19 Billion (And Increasing) Toxic Asset Sink Hole
By:
Tyler Durden
The Scariest Thing On Wall Street - FNM
By:
The Growth Stock Wire
Natural Gas Companies
By:
Keith Kohl
Hot Stocks: Google’s Drive For Dominance Extends Into The Burgeoning Smartphone Market
By:
Money Morning
Advertisement
Special Offers
Recent Articles by TraderMark
Wells Fargo (WFC) Kicks The Can By Transofrming Option ARM Mortgages Into Interest Only
Official Unemployment Rate Hits 10.2%; Reality Is Far Higher
Blue Coat Systems (BCSI) - More Global Labor Arbitrage
Yet Another "V" Shaped Bounce- Old Patterns Seem Useless
Still Many Broken Charts Despite The Index Rallies; Russell 2000 Under Performing
Market Jumps Back Over 50 Day Moving Average As Investors Predict More Easy Money
More Articles by:
TraderMark
More Articles on:
Medical
,
Aerospace
Research Related Stocks:
AVAV
,
EBS
,
VXGN
,
Subscribe to
Email Alerts
or
RSS feeds
for articles from more than 300 contributors and press releases, SEC filings and full text news from thousands of sources.
{1}
##LOC[OK]##
{1}
##LOC[OK]##
##LOC[Cancel]##
{1}
##LOC[OK]##
##LOC[Cancel]##
Fundamental data is provided by
Zacks Investment Research
, market data is provided by
AlphaTrade.
, and Commentary and Press Releases provided by
Quotemedia